Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
iTeos Therapeutics
With
iTeos Belgium SA
Merck Sharp & Dohme LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding participation in the Trial, please refer to your physician
Women and men ≥18 years of age with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Subject with histologically or cytologically confirmed advanced solid tumor for whom no standard treatment is further available.
At least 4 weeks since any previous treatment for cancer
Subject must consent to pretreatment and on treatment tumor biopsies
Adequate organ and marrow function
You may not be if
Patients with primary brain tumors or primary tumors with central nervous system metastases as only location of disease. Controlled brain metastases are permitted
Participants with second/other active cancers requiring current treatment
Uncontrolled/significant heart disease
Known History of chronic hepatitis, Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except participants with liver cancer) or Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS)
Active/uncontrolled autoimmune disease
Active infection
Clareo Health | First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer
